TARA - NASDAQ

Protara Therapeutics, Inc.

TARA·NASDAQ

$4.34

+3.2%

HealthcareBiotechnology

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$167.48M

EPS-1.3400

P/E Ratio-3.97

Earnings Date07/30/2026

tara

Net Common Stock Issuance

Last Annual Value

82.90M

3-Year CAGR

874%

5-Year CAGR

-1%

10-Year CAGR

86%

Adjust for Inflation

Protara Therapeutics, Inc. Competitors Analysis of Net Common Stock Issuance

TARA · NASDAQ

Company	Net Common Stock Issuance	CAGR 3Y	CAGR 5Y	CAGR 10Y
Protara Therapeutics, Inc. NASDAQ:TARA	82.90M	N/A	N/A	82.0%
Assembly Biosciences, Inc. NASDAQ:ASMB	174.67M	133.7%	27.0%	102.2%
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	77.43M	1031.8%	4.3%	16.6%
Immuneering Corporation NASDAQ:IMRX	226.58M	100.3%	13.5%	N/A
Pyxis Oncology, Inc. NASDAQ:PYXS	742.00K	-50.5%	-65.5%	N/A
Prelude Therapeutics Incorporated NASDAQ:PRLD	25.04M	-43.1%	-31.1%	N/A
Invivyd, Inc. NASDAQ:IVVD	215.63M	N/A	-8.2%	N/A
Orchestra BioMed Holdings, Inc. NASDAQ:OBIO	71.97M	556.8%	N/A	N/A
Codexis, Inc. NASDAQ:CDXS	18.03M	27.7%	29.4%	N/A
OmniAb, Inc. NASDAQ:OABI	28.36M	N/A	N/A	N/A
Sangamo Therapeutics, Inc. NASDAQ:SGMO	74.01M	69.8%	22.3%	52.2%

Protara Therapeutics, Inc. Fair Value Envelope

TARA · NASDAQ

Our analysis suggests that TARA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.34, this represents a potential HIDDEN relative to our calculated worth for Protara Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $4.34

Related Guides

Blog Categories

Continue your TARA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.